Bayer, ISN launches kidney health awareness campaign
Written by Arushi Sharma
Bayer and the International Society of Nephrology (ISN) are teaming up to fight Chronic Kidney Disease (CKD) in India. With diabetes being a major risk factor, the campaign highlights the importance of early detection and proper management, especially for India's diabetic population.
Bayer and the International Society of Nephrology (ISN) have joined forces to launch a significant kidney health awareness campaign in India, aiming to tackle the escalating concern of Chronic Kidney Disease (CKD).
According to the ISN, CKD currently affects approximately 17 percent of India’s population, posing profound challenges to public health and healthcare finances.
The campaign emphasizes the crucial link between diabetes and CKD, highlighting that one in three adults with diabetes also suffers from CKD. Given CKD's complexity, tailored approaches to care are deemed necessary across India, with diagnostic tools such as the Urine Albumin-to-Creatinine Ratio (UACR) test playing a pivotal role in early detection.
In a bid to address the urgency of the situation, Bayer and ISN orchestrated a gathering of stakeholders in India on World Kidney Day, rallying support to combat CKD progression among diabetic patients.
Central to their efforts was the ongoing campaign #ReadyToSlowDown, which was initially launched last year. During a media conclave organized as part of this initiative, representatives from both organizations urged India’s over 10-crore diabetes patients to prioritize kidney health.
Dr. Sanjeev Gulati from Fortis Escorts, Delhi, shed light on the silent CKD epidemic prevalent in India, particularly among marginalized communities. He underscored the significance of early detection and advocated for lifestyle changes among high-risk patients, such as those with diabetes.
Further insights were provided by Dr. Anil Bhansali from PGIMER Chandigarh, who elucidated the critical link between diabetes management and kidney health, emphasizing the imperative of early intervention.
Shweta Rai, Managing Director of Bayer Zydus Pharma, reiterated Bayer's commitment to enhancing kidney health in India through targeted awareness campaigns and patient-centric initiatives.
The collaborative efforts of Bayer and ISN, alongside the insights shared by healthcare professionals, underscore the importance of proactive measures in tackling the growing burden of CKD, particularly among diabetic populations in India.